SCHOLAR ROCK HOLDING CORPORATION Stock-Based Compensation
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Stock-Based Compensation of $37.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $19.66M, a 19.53% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $18.25M, a 36.02% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $19.42M, a 104.41% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $18.33M, a 89.96% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for fiscal 2025 was $75.60M, a 106.40% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for fiscal 2024 was $36.63M, a 34.95% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for fiscal 2023 was $27.14M, a 2.02% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, noncash expense for fiscal 2022 was $27.70M, a 19.66% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $37.91M 10-Q · filed 2026-08-06 | $57.33M derived: sum of 3 quarters · filed 2026-08-06 | $75.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.25M 10-Q · filed 2026-05-07 | $37.67M derived: sum of 2 quarters · filed 2026-05-07 | $56.00M derived: sum of 3 quarters · filed 2026-05-07 | $80.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $37.75M derived: sum of 2 quarters · filed 2026-03-03 | $62.19M derived: sum of 3 quarters · filed 2026-08-06 | $75.60M 10-K · filed 2026-03-03 |
| 2025-09-30 | $18.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $42.76M derived: sum of 2 quarters · filed 2026-08-06 | $56.18M 10-Q · filed 2025-11-14 | $65.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $24.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $37.85M 10-Q · filed 2026-08-06 | $47.35M derived: sum of 3 quarters · filed 2026-08-06 | $57.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $13.41M 10-Q · filed 2026-05-07 | $22.91M derived: sum of 2 quarters · filed 2026-05-07 | $32.56M derived: sum of 3 quarters · filed 2026-05-07 | $41.88M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $19.15M derived: sum of 2 quarters · filed 2026-03-03 | $28.46M derived: sum of 3 quarters · filed 2026-03-03 | $36.63M 10-K · filed 2026-03-03 |
| 2024-09-30 | $9.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $18.96M derived: sum of 2 quarters · filed 2025-11-14 | $27.13M 10-Q · filed 2025-11-14 | $34.08M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $9.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $17.48M 10-Q · filed 2025-08-06 | $24.43M derived: sum of 3 quarters · filed 2025-08-06 | $31.63M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $8.16M 10-Q · filed 2025-05-14 | $15.12M derived: sum of 2 quarters · filed 2025-05-14 | $22.32M derived: sum of 3 quarters · filed 2025-05-14 | $29.14M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $6.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.15M derived: sum of 2 quarters · filed 2025-02-27 | $20.97M derived: sum of 3 quarters · filed 2025-02-27 | $27.14M 10-K · filed 2025-02-27 |
| 2023-09-30 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $14.02M derived: sum of 2 quarters · filed 2024-11-12 | $20.19M 10-Q · filed 2024-11-12 | $26.36M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $12.99M 10-Q · filed 2024-08-08 | $19.15M derived: sum of 3 quarters · filed 2024-08-08 | $27.07M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $6.17M 10-Q · filed 2024-05-07 | $12.34M derived: sum of 2 quarters · filed 2024-05-07 | $20.25M derived: sum of 3 quarters · filed 2024-05-07 | $27.04M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $14.08M derived: sum of 2 quarters · filed 2024-03-19 | $20.87M derived: sum of 3 quarters · filed 2024-03-19 | $27.70M 10-K · filed 2024-03-19 |
| 2022-09-30 | $7.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $14.71M derived: sum of 2 quarters · filed 2023-11-07 | $21.54M 10-Q · filed 2023-11-07 | $27.63M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $13.62M 10-Q · filed 2023-08-09 | $19.71M derived: sum of 3 quarters · filed 2023-08-09 | $25.87M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $6.83M 10-Q · filed 2023-05-09 | $12.92M derived: sum of 2 quarters · filed 2023-05-09 | $19.08M derived: sum of 3 quarters · filed 2023-05-09 | $25.30M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $12.25M derived: sum of 2 quarters · filed 2023-03-07 | $18.48M derived: sum of 3 quarters · filed 2023-03-07 | $23.15M 10-K · filed 2023-03-07 |
| 2021-09-30 | $6.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $12.38M derived: sum of 2 quarters · filed 2022-11-14 | $17.05M 10-Q · filed 2022-11-14 | $19.58M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $6.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $10.90M 10-Q · filed 2022-08-08 | $13.43M derived: sum of 3 quarters · filed 2022-08-08 | $17.46M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $4.67M 10-Q · filed 2022-05-16 | $7.20M derived: sum of 2 quarters · filed 2022-05-16 | $11.24M derived: sum of 3 quarters · filed 2022-05-16 | $13.63M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $6.57M derived: sum of 2 quarters · filed 2022-03-07 | $8.96M derived: sum of 3 quarters · filed 2022-03-07 | $11.18M 10-K · filed 2022-03-07 |
| 2020-09-30 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.43M derived: sum of 2 quarters · filed 2021-11-09 | $8.64M 10-Q · filed 2021-11-09 | $10.50M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $4.61M 10-Q · filed 2021-08-10 | $6.46M derived: sum of 3 quarters · filed 2021-08-10 | $9.15M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $2.21M 10-Q · filed 2021-05-13 | $4.07M derived: sum of 2 quarters · filed 2021-05-13 | $6.75M derived: sum of 3 quarters · filed 2021-05-13 | $8.57M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $4.54M derived: sum of 2 quarters · filed 2021-03-09 | $6.35M derived: sum of 3 quarters · filed 2021-03-09 | $7.97M 10-K · filed 2021-03-09 |
| 2019-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $4.50M derived: sum of 2 quarters · filed 2020-11-09 | $6.12M 10-Q · filed 2020-11-09 | $8.27M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $3.43M 10-Q · filed 2020-08-07 | $5.59M derived: sum of 3 quarters · filed 2020-08-07 | $7.07M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $1.62M 10-Q · filed 2020-05-07 | $3.77M derived: sum of 2 quarters · filed 2020-05-07 | $5.26M derived: sum of 3 quarters · filed 2020-05-07 | $6.35M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $3.64M derived: sum of 2 quarters · filed 2020-03-12 | $4.73M derived: sum of 3 quarters · filed 2020-03-12 | $5.21M 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $2.58M derived: sum of 2 quarters · filed 2019-11-12 | $3.06M 10-Q · filed 2019-11-12 | $3.85M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $1.57M 10-Q · filed 2019-08-14 | $2.36M derived: sum of 3 quarters · filed 2019-08-14 | $2.56M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $482.00K 10-Q · filed 2019-05-15 | $1.27M derived: sum of 2 quarters · filed 2019-05-15 | $1.48M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | $793.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $994.00K derived: sum of 2 quarters · filed 2019-03-19 | $1.48M 10-K · filed 2019-03-19 | |
| 2017-09-30 | $201.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $689.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $488.00K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |